GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (TSX:LABS) » Definitions » Gross Margin %

MediPharm Labs (TSX:LABS) Gross Margin % : 31.84% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. MediPharm Labs's Gross Profit for the three months ended in Sep. 2024 was C$3.12 Mil. MediPharm Labs's Revenue for the three months ended in Sep. 2024 was C$9.80 Mil. Therefore, MediPharm Labs's Gross Margin % for the quarter that ended in Sep. 2024 was 31.84%.


The historical rank and industry rank for MediPharm Labs's Gross Margin % or its related term are showing as below:

TSX:LABS' s Gross Margin % Range Over the Past 10 Years
Min: -122.12   Med: -8.65   Max: 33.2
Current: 29.16


During the past 7 years, the highest Gross Margin % of MediPharm Labs was 33.20%. The lowest was -122.12%. And the median was -8.65%.

TSX:LABS's Gross Margin % is ranked worse than
79.63% of 962 companies
in the Drug Manufacturers industry
Industry Median: 47.1 vs TSX:LABS: 29.16

MediPharm Labs had a gross margin of 31.84% for the quarter that ended in Sep. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for MediPharm Labs was 0.00% per year.


MediPharm Labs Gross Margin % Historical Data

The historical data trend for MediPharm Labs's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Gross Margin % Chart

MediPharm Labs Annual Data
Trend Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 33.20 -122.12 -70.22 -8.65 17.71

MediPharm Labs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.42 24.05 27.13 33.02 31.84

Competitive Comparison of MediPharm Labs's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediPharm Labs's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Gross Margin % distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's Gross Margin % falls into.



MediPharm Labs Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

MediPharm Labs's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=5.9 / 33.062
=(Revenue - Cost of Goods Sold) / Revenue
=(33.062 - 27.207) / 33.062
=17.71 %

MediPharm Labs's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=3.1 / 9.798
=(Revenue - Cost of Goods Sold) / Revenue
=(9.798 - 6.678) / 9.798
=31.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


MediPharm Labs  (TSX:LABS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MediPharm Labs had a gross margin of 31.84% for the quarter that ended in Sep. 2024 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


MediPharm Labs Gross Margin % Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MediPharm Labs Business Description

Traded in Other Exchanges
Address
151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.
Executives
Keith Strachan Director
Gregory Edison Hunter Senior Officer
David Pidduck Director, Senior Officer
Bryan Howcroft Director, Senior Officer
Patrick Mccutcheon Director
Warren Everitt Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Etf Managers Trust 10% Security Holder
Christopher David Taves Director
Sybil Taylor Senior Officer
Braden Fenske Senior Officer
David John Mayers Senior Officer

MediPharm Labs Headlines